Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 92% Improvement Relative Risk Kerr et al. Ivermectin for COVID-19 Prophylaxis Is prophylaxis with ivermectin beneficial for COVID-19? PSM retrospective 566 patients in Brazil (July - December 2020) Lower mortality with ivermectin (p=0.0008) Kerr et al., Cureus, doi:10.7759/cureus.28624 Favors ivermectin Favors control
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Kerr et al., Cureus, doi:10.7759/cureus.28624 (date from earlier preprint)
Kerr et al., Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in.., Cureus, doi:10.7759/cureus.28624 (date from earlier preprint)
Feb 2022   Source   PDF  
  All Studies   Meta
PSM multivariable analysis of the Itajaí trial showing significantly lower mortality with regular use of ivermectin prophylaxis. Immortal time bias may significantly affect these results.
risk of death, 92.0% lower, RR 0.08, p < 0.001, treatment 2 of 283 (0.7%), control 15 of 283 (5.3%), NNT 22, adjusted per study, strictly regular use vs. non-use, propensity score matching, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kerr et al., 6 Feb 2022, retrospective, propensity score matching, multivariable, Brazil, peer-reviewed, 9 authors, study period 7 July, 2020 - 2 December, 2020, dosage 200μg/kg days 1, 2, 16, 17, 0.2mg/kg/day for 2 days every 15 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: See discussions, stats, and author profiles for this publication at: Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90% reduction in COVID-19 mortality rate, in a dose-response manner: definitive results of a prospective o... Preprint · February 2022 DOI: 10.13140/RG.2.2.20069.68320 CITATIONS READ 0 1 9 authors, including: Lucy Kerr Fernando Baldi Instituto Kerr São Paulo State University 15 PUBLICATIONS 98 CITATIONS 431 PUBLICATIONS 4,650 CITATIONS SEE PROFILE SEE PROFILE Raysildo Barbosa Lôbo Juan Chamie Center for Genetic Engineering and Biotechnology Universidad EAFIT 186 PUBLICATIONS 1,196 CITATIONS 14 PUBLICATIONS 22 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: Análise genômica de bovinos da raça Nelore (Bos indicus) para características quantitativas e qualitativas de carcaça e carne View project Beth Israel work View project All content following this page was uploaded by Cadegiani Flávio on 06 February 2022. The user has requested enhancement of the Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90% reduction in COVID-19 mortality rate, in a dose-response manner: definitive results of a prospective observational study of a strictly controlled 223,128 population from a city-wide program in Southern Brazil. Lucy Kerr, MD, ARDMS1, Fernando Baldi, PhD2, Raysildo Barbosa Lôbo, PhD3, Washington Luiz Olivato Assagra4, Fernando Carlos Proença5, Jennifer A. Hibberd, DDS, DPD, MRCDC6, Juan J Chamie-Quintero7, Pierre Kory, MD, MPA8, Flavio A. Cadegiani, MD, MSc, PhD8,9* 1 Instituto Kerr de Ensino e Pesquisa, São Paulo, Brazil Department of Animal Sciences, State University of São Paulo, São Paulo, Brazil 3 Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. 4 Centro Técnico de Avaliação Genômica C.T.A.G, Ribeirão Preto, Brazil 5 Itajaí City Hall, Itajaí, Brazil 6 University of Toronto, Toronto, Canada 7 Data Analysis, Universidad EAFIT, Cambridge, USA 8 Front-Line Covid-19 Critical Care Alliance (FLCCC), USA 9 Corpometria Institute, Brasilia, Brazil 2 *Corresponding author: Flávio A. Cadegiani, MD, MSc, PhD Corpometria Institute SGAS 915 Centro Clínico Advance, Rooms 260/262/264, Brasília, DF, Brazil,, +55 61 981.395.395 Key-words: COVID-19, SARS-CoV-2, ivermectin, prophylaxis, prevention, coronavirus Abstract Background: Previously, we demonstrated that ivermectin use as prophylaxis for COVID-19 was associated with reductions in COVID-19 infection, hospitalization, and mortality rates, and in the risk of dying from COVID-19, irrespective of regularity and accumulated use of ivermectin, in an observational, prospectively obtained data from a strictly controlled city-wide program in a city in Southern Brazil (Itajaí, SC, Brazil) of of medically-based, optional use of ivermectin as prophylaxis for COVID-19. In this study, our objective was to explore the data obtained from the program to evaluate whether the level of regularity of ivermectin use impacted in the reductions in these outcomes, aiming to determine if ivermectin showed a progressive dose-, regularity-response in terms of protection from COVID-19 and COVID-19 related outcomes. Materials and methods: This is a prospective observational study..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop